热门资讯> 正文

展望Therapeutics 2026年第三季度盈利预览

2026-08-14 02:43

Outlook Therapeutics (OTLK) is scheduled to announce Q3 earnings results on Friday, August 14th, before market open.
The consensus EPS Estimate is -$0.07 (+84.1% Y/Y) and the consensus Revenue Estimate is $0.97M (-35.8% Y/Y).
Over the last 1 year, OTLK has beaten EPS estimates 50% of the time and has beaten revenue estimates 0% of the time.
Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward. Revenue estimates have seen 0 upward revisions and 2 downward.

More on Outlook Therapeutics

Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needs
Outlook Therapeutics Heads Into Another FDA PDUFA Decision For Lytenava
Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity
Outlook Therapeutics slides after pricing $55M securities offering
Outlook gains as wet AMD therapy reconsidered for FDA review

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。